financetom
JNJ
financetom
/
Healthcare
/
JNJ
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Johnson & JohnsonJNJ
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.

The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand.

It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension.

This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use.

Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand.

This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Latest News >
What 5 Analyst Ratings Have To Say About Cipher Mining
What 5 Analyst Ratings Have To Say About Cipher Mining
Aug 14, 2024
Throughout the last three months, 5 analysts have evaluated Cipher Mining ( CIFR ) , offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings...
BRIEF-Wiz Labors To Hire A CFO, Making An IPO Before 2026 Unlikely- The Information
BRIEF-Wiz Labors To Hire A CFO, Making An IPO Before 2026 Unlikely- The Information
Aug 14, 2024
Aug 14 (Reuters) - * WIZ LABORS TO HIRE A CFO, MAKING AN IPO BEFORE 2026 UNLIKELY- THE INFORMATION Source: https://tinyurl.com/3vt7kjm4 ...
European Wax Center Names David Berg CEO
European Wax Center Names David Berg CEO
Aug 14, 2024
09:20 AM EDT, 08/14/2024 (MT Newswires) -- European Wax Center ( EWCZ ) said Wednesday that the board named David Berg its chief executive, succeeding David Willis. The company said Berg, whose appointment took effect Monday, will also continue serving as its executive chairman. Berg previously served as the company's CEO from 2018 to 2023, European Wax Center ( EWCZ...
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?
Aug 14, 2024
Wednesday, Viracta Therapeutics Inc. ( VIRX ) stock is trading higher after the company reported Phase 2 NAVAL-1 trial results from Stages 1 and 2 of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort. Twenty-one patients with primarily Stage III-IV disease received nanatinostat in combination with valganciclovir. As of the June 28 data cutoff, combined...
Copyright 2023-2026 - www.financetom.com All Rights Reserved